Korea recognizes ginseng for bone health
The Korean Ministry of Food and Drug Safety recently released a statement saying that ginseng was previously recognized for its ability to help improve immune system health and relieve fatigue. Currently, ginseng can claim 3 health claims in Korea: improving immune health, relieving fatigue, and improving bone health.
As a functional ingredient for improving bone health, ginseng extract contains 25 mg of ginsenoside Rg1 and Rb1 complex. The claim was released after research was presented on ginseng's ability to improve bone health. The 12-week study, led by the Korea Rural Development Agency (RDA), will continue to investigate new functions of ginseng while supporting its use on an industrial scale.
Ginseng, which has a relatively low value compared to red ginseng, would greatly boost ginseng consumption if it were developed into a variety of functional health foods. This is in line with Korea's overall strategy to promote the export of domestically produced functional health foods, of which ginseng is one.
2026-10-15
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Enhance the National Cultural Soft Power to Promote Chinese Food Culture going out
-
FDA Lifts Administrative Stay, Restoring Red No. 3 Ban Timeline for Food and Ingested Drugs
-
A Fake Email Drains RMB 12 Million: Asia’s Waterproof Giant’s Overseas ‘Payment Heist’ Exposes the Fatal Blind Spot of Chinese Corporate Globalization
-
EU Chemicals Regulatory Update: Practical Compliance Actions Following ECHA January 2026 Developments
-
UK’s £350 Million Critical Chemicals Fund Enters Formal Review, Offering Up to 50% Support Per Project
-
U.S. Imposes 12.5% Additional Tariff! Nutritional Ingredients Including Creatine, Taurine, and Glucosamine Included in New Section 301 Tariff List
-
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
-
China NMPA Issues Priority Review Pathway for Four Categories of Chemical Active Pharmaceutical Ingredients, Effective August 1, 2026
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
2026 Q1 Chemical Giant Earnings: Supply Contraction, Flat Demand, Full-Scale "Defense Priority"
Recommend Reading
-
WACKER’s 2025 Loss Reaches €805 Million as the PACE Cost-Cutting Plan Becomes the Key Variable for 2026
-
Syngenta Bee Pesticide Protest Shows the Pressure Building Around Crop Protection Giants
-
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
FDA’s Review of BHT and ADA Signals a New Era for Food Additive Compliance
-
South Korea’s Largest Petrochemical Hub Moves to Cut Cracker Capacity by 40%
-
China's Acetone Market Reverses Decline and Rises
-
Weak Balance Under Cost Support—Melamine Market Struggles to Stay Firm
-
This Week, the Transaction Focus of China's Propylene Oxide Market Rises (11.17-11.21)
-
This Week's Epichlorohydrin Market Stably Weak (11.17-11.21)
-
Weaker Costs, Mild Demand Pressure Keep Polyester Short-Fiber Price Focus Lower